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ABSTRACT 
 
 
 
Coffey, Barbara M. M.S., Purdue University, August 2011.  Dual Functions of the 
Protein MgtE in Pseudomonas aeruginosa.  Major Professor:  Gregory G. Anderson. 
 
 
 
The Gram-negative bacterium Pseudomonas aeruginosa is an opportunistic pathogen 
which readily establishes itself in the lungs of people with cystic fibrosis (CF).  Most CF 
patients have life-long P. aeruginosa infections.  By modulating its own virulence and 
forming biofilms, P. aeruginosa is able to evade both host immune responses and 
antibiotic treatments.  Previous studies have shown that the magnesium transporter MgtE 
plays a role in virulence modulation by inhibiting transcription of the type III secretion 
system, a mechanism by which bacteria inject toxins directly into the eukaryotic host cell.  
MgtE had already been identified as a magnesium transporter, and thus its role in 
regulating cytotoxicity was indicative of dual functions for this protein.  This research 
focused on a structure-function analysis of MgtE, with the hypothesis that the magnesium 
transport and cytotoxicity functions could be exerted independently.  Cytotoxicity assays 
were conducted using a co-culture model system of cystic fibrosis bronchial epithelial 
cells and a ∆mgtE strain of P. aeruginosa transformed with plasmids carrying wild type 
or mutated mgtE.  Magnesium transport was assessed using the same mgtE plasmids in a 
Salmonella strain deficient in all magnesium transporters.  Through analysis of a number 
of mgtE mutants, we found two constructs – a mutation in a putative magnesium binding 
ix 
site, and an N-terminal truncation – which demonstrated a separation of functions.  We 
further demonstrated the uncoupling of functions by showing that different mgtE mutants 
vary widely in their ability to regulate cytotoxicity, whether or not they are able to 
transport magnesium.  Overall, these results support the hypothesis of MgtE as a dual 
function protein and may lead to a better understanding of the mechanisms underlying P. 
aeruginosa virulence.  By understanding virulence mechanisms, we may be able to 
develop treatments to reduce infections and pave the way to better health for people with 
cystic fibrosis. 
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CHAPTER 1:  INTRODUCTION 
 
 
 
1.1  Cystic Fibrosis 
Cystic fibrosis (CF) is an autosomal recessive disease caused by a mutation in the 
gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR).  In the 
United States, CF occurs in approximately 1 in 3900 births, with the disease being most 
common among Caucasians at a rate of 1 in 2500 births [1].  Currently, the average life 
expectancy for an individual with CF is 37 years [2]. 
In CF, non-functional CFTR fails to conduct chloride ions and results in numerous 
pathologies throughout the body.  In the lungs, CFTR dysfunction leads to the build-up of 
a thick mucus layer, which impairs cilia movement and diminishes the ability to clear 
pathogens.  The bacterium Pseudomonas aeruginosa is able to resist both the host’s 
immune system and antibiotic treatment, and as a consequence, chronic pulmonary 
infection is a major cause of morbidity and mortality for individuals with CF.  Although 
several bacteria are known to cause lung infections, P. aeruginosa is the most 
predominant pathogen found in CF patients [2, 3].  Adding yet another layer of 
complexity to the interaction between P. aeruginosa and its host, the bacterium 
undergoes phenotypic changes in the CF lung as the infection evolves from acute to 
chronic, during which time P. aeruginosa regulates its own virulence mechanisms in 
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order to persist in its host [4, 5].  These include changes in secretions of toxins and 
exopolysaccharides, and formation of biofilms. 
There is currently no cure for cystic fibrosis.  One of the limitations of research on CF 
is the lack of a good animal model.  Mice have been used in CF research, but the murine 
lung does not express a CF phenotype similar to humans.  More recently, ferrets and pigs 
with CF have been developed, but there are enormous challenges to breeding and 
maintaining these animals [6].  In the absence of a practical animal model, tissue culture 
is a highly valuable research tool for CF lung infection.  Potential for medical treatment 
of chronic lung infection and improved health for CF patients lies in better understanding 
of P. aeruginosa virulence mechanisms, much of which we hope to understand through 
in vitro experimentation. 
 
1.2  Cystic Fibrosis Transmembrane Conductance Regulator 
Encoded on human chromosome 7, the CFTR protein contains 1480 amino acids and 
has a molecular weight of 168 kDa [7].  It is a chloride channel located in epithelial cells 
throughout the body, and belongs to the ATP-binding cassette transporter (ABC-
transporter) family of proteins.  Over 1700 mutations of CFTR have been found, with the 
mutation ∆F508 being most often identified and attributed to approximately 75% of CF 
cases [2].  ∆F508 is a deletion of the amino acid phenylalanine at position 508 in the 
protein.  This mutation leads to a misfolded and defective protein, which is quickly 
degraded [8]. 
Some reports have suggested that defective CFTR impairs innate immune response, 
thereby implicating this protein in the facility with which P. aeruginosa initially infects 
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the CF lung [9-11].  These studies assert that normal CFTR is able to recognize the 
pathogen, signal epithelial cells to activate transcription factor NF-κB, and initiate an 
immune response.  Abnormal CFTR is unable to induce this response and therefore leads 
to immunological deficiency. 
The tissue cultures used in this research are grown from human-derived cystic fibrosis 
bronchial epithelial (CFBE) cells that express the CFTR ∆F508 mutation.  
 
1.3  The Bacterium Pseudomonas aeruginosa 
P. aeruginosa is a Gram-negative bacterium commonly found in both natural and 
man-made environments.  It is a versatile, adaptable opportunistic pathogen with a large 
genome (6.3 million base pairs) encoding approximately 5500 genes [12].  Although 
typically non-virulent to healthy individuals, P. aeruginosa causes numerous types of 
infections in immunocompromised individuals, including burn infections, nosocomial 
infections such as pneumonia and catheter-related urinary-tract infections, and chronic, 
antibiotic-resistant lung infections in people with CF [13].  Chronic P. aeruginosa 
infection has been recognized in CF patients since the 1970s, and the presence of 
different phenotypes was also noted [14].  It has since been elucidated that P. aeruginosa 
undergoes phenotypic changes and differentially regulates its own virulence factors 
during the course of infection in the CF lung [15].  Bacterial gene expression varies 
according to whether the infection is acute or chronic, such that the bacterium which 
initially enters the host and establishes infection is markedly different from the bacterium 
that maintains itself and persists, possibly for decades, in the same host [16, 17].  It has 
been found that as the infection endures and the patient’s age progresses, the lung 
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microbial community loses diversity and becomes increasingly dominated by P. 
aeruginosa, although within a single patient, there may exist multiple P. aeruginosa 
phenotypes [18, 19]. 
“Conversion to mucoidy” is a term which refers to the transition of the bacteria from 
a planktonic, free-floating state to a colonizing, alginate-producing phenotype.  The 
mucoid form of P. aeruginosa secretes an exopolysaccharide that aids in protection 
against the host’s immune cells, forms a barrier against antibiotics, and helps in the 
initiation of biofilm formation.  Mucoid P. aeruginosa in the lungs of CF patients is 
indicative of deteriorating lung function and declining patient condition [14, 20-22]. 
The P. aeruginosa strain used in this study is PA14, identified by Rahme et al. in 
1995 [23].  This strain was initially discovered among a screen of 30 human clinical 
isolates and was shown to elicit pathogenicity in both mice and Arabidopsis.  PA14 was 
selected for further study due to its unique characterization as a dual plant-animal 
pathogen.  PA14 is a non-mucoid strain, but has been shown to form biofilms [24].  Both 
mucoid and non-mucoid P. aeruginosa can form biofilms, but the biofilms formed by 
mucoid P. aeruginosa are impossible to eradicate from the CF lung [25].  The numerous 
phenotypes of P. aeruginosa found in the various stages of infection make the study of 
this bacterium even more challenging. 
The progression of CF lung disease and the accompanying microbiology are 
tremendously complex.  It remains to be fully understood why P. aeruginosa dominates 
over other bacteria in the CF lung.  For this reason, there is ample need to continue 
research efforts toward illuminating P. aeruginosa virulence mechanisms in the CF lung 
environment.  
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1.4  Biofilms 
Biofilms are a remarkably successful microbial survival mechanism.  A biofilm is a 
colony of bacteria that has transitioned from a planktonic (free-swimming) state to a 
fixed, surface-attached state.  The surface to which the biofilm attaches may be biotic or 
abiotic.  The process of biofilm formation takes place in a number of distinct stages, 
brought about through differential expression of bacterial genes in response to their 
environment [26]. 
The components of a biofilm vary depending on the environment, but biofilms are 
generally comprised of living bacteria, exopolysaccharides, and macromolecules 
arranged within an intricate matrix that provides a protective structure as well as a system 
of channels allowing for the diffusion of water, nutrients, and metabolic waste [27-29].  
Recent analysis has shown that the extracellular matrix of P. aeruginosa PA14 is 
composed largely of DNA and lipopolysaccharides (LPS) [24].  In this study and 
numerous others, PA14 has been used for laboratory research due to its strong biofilm-
forming ability. 
When the transition to a biofilm state occurs within a human host, the infection 
condition evolves from acute to chronic.  As a biofilm forms in the lungs of a CF patient, 
a complex bacterial community develops that is highly resistant to the host’s immune 
system and antibiotic treatment.  It is thought that the longer the biofilm remains, the 
more antibiotic resistant it becomes [30].  Much remains to be understood about how 
bacteria regulate this process, and why P. aeruginosa biofilms in particular thrive in the 
environment of the CF lung.   
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Biofilm formation and chronic lung infection is a serious problem for CF patients, 
causing permanent lung damage that leads to decline in patient condition and ultimately 
death.  Although biofilms lack the virulence factors attributed to planktonic bacteria, they 
are nevertheless highly destructive to the host.  The decreased cytotoxicity of the bacteria 
in biofilms is one of the adaptations that allows them to persist.  Previous studies indicate 
that deletion of the gene encoding the protein MgtE from P. aeruginosa increases the 
cytotoxicity of biofilms, although it does not impact biofilm formation [31]. 
 
1.5  MgtE 
MgtE is a magnesium-transport protein found in all domains of life.  The groundwork 
already done to understand the role of MgtE in prokaryotes has been carried out in 
several bacterial species, and although P. aeruginosa MgtE is thought to function in a 
similar manner, it has not been fully characterized.  When first identified in 1995 in the 
Gram-positive bacterium Bacillus firmus, MgtE was immediately recognized as a unique 
protein, unrelated to any other previously characterized family of magnesium transporters 
[32].  The crystal structure (Figure 1) was resolved in Thermus thermophilus [33], and the 
peptide sequence is 29% identical in P. aeruginosa;  therefore, our current understanding 
of MgtE in P. aeruginosa is by analogy. 
P. aeruginosa MgtE has a molecular mass of 54 kDa and is suggested to function as a 
homodimer.  The carboxy-terminal transmembrane domain of the monomer includes five 
alpha-helices which form a transmembrane pore when dimerized.  The cytosolic amino-
terminus includes several globular domains which work cooperatively to sense 
intracellular magnesium levels.  The transmembrane and cytosolic domains are joined by 
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a third region called the connecting, or plug, helix.  The current model of MgtE suggests 
a significant conformational change between the magnesium-bound and unbound states.  
The binding of magnesium to the cytosolic domains affects movement of the connecting 
helices, which then leads to opening or closing of the transmembrane pore [34].  It has 
been shown that the MgtE pore is highly specific for magnesium ions and is not regulated 
by other divalent cations such as calcium, although there is some evidence of sensitivity 
to Co2+ [32, 34]. 
P. aeruginosa expresses other magnesium transporters.  CorA is constitutively 
expressed and is the primary mediator of magnesium influx.  CorA has also been shown 
to mediate magnesium efflux in Gram-negative bacteria when intracellular magnesium 
concentrations approach 1mM [35-38].  Two other proteins, MgtA and MgtC are thought 
to mediate magnesium influx only, but MgtE is unrelated to these proteins [32, 39].  
Although magnesium is essential to life, magnesium transport proteins and the regulation 
of magnesium homeostasis are not yet fully understood. 
While well-established as a magnesium transporter, MgtE in P. aeruginosa has also 
been shown to play a role in regulating virulence, and it has been suggested that the two 
functions, magnesium transport and regulation of cytotoxicity, may be separable.  This 
was initially demonstrated by Anderson et al. in experiments with an mgtE construct 
containing a C-terminal His6 tag.  This mutant was unable to transport magnesium; 
however, it did regulate cytotoxicity.  These studies connected the effect of increased 
cytotoxicity to an increase in the expression of the type III secretion system [31].  
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1.6  Type III Secretion System 
The type III secretion system (T3SS) in P. aeruginosa is a large protein complex, 
often described as a needle-like structure, which enables the pathogen to inject cytotoxic 
effector molecules directly into its eukaryotic host.  This system mediates acute 
infections such as hospital-acquired pneumonia, but has been found to be diminished in 
adult CF patients with long-term P. aeruginosa infection.  In simplest terms, the longer P. 
aeruginosa infection persists, the less it expresses T3SS [4]. 
Currently, there are four known effectors of the P. aeruginosa type III secretion 
system:  ExoS, ExoT, ExoU, and ExoY.  It appears that all four are not usually encoded 
in the genome of a single strain.  Their cytotoxic effects on host cells are achieved 
through a variety of mechanisms including phospholipase, adenylate cyclase, and 
GTPase-activating protein (GAP) activities, as well as numerous other disruptions of host 
cell functions.  Among the four effectors, ExoU is the most cytotoxic and rapidly causes 
host cell death.  Consistent with the idea that P. aeruginosa downregulates its virulence 
as infection persists, ExoU-producing strains are not often found in chronically infected 
CF patients [13, 40]. 
 
1.7  Research Goals 
The goal of this research was to better understand the functional interactions of the 
MgtE domains and how they relate to magnesium transport and cytotoxicity, with the 
hypothesis that the magnesium transport and cytotoxicity functions of P. aeruginosa 
MgtE can work independently of each other.  Cytotoxicity, more specifically, should be 
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tested in the context of the CFTR mutation, since our interest is focused on understanding 
the unique virulence behaviors of P. aeruginosa in people with CF. 
The hypothesis was tested by doing a structure-function analysis of MgtE and 
demonstrating which regions of the protein were essential for magnesium transport and 
which were essential for regulation of cytotoxicity.  All assays for cytotoxicity were 
performed on cystic fibrosis bronchial epithelial cells (CFBE) that express the CFTR 
∆F508 mutation.  The research process was guided by three specific aims: 
• Specific Aim 1:  Test the effect of C-terminal truncations on the ability of MgtE 
to transport magnesium and inhibit cytotoxicity toward CFBE. 
• Specific Aim 2:  Test the effect of N-terminal truncations on the ability of MgtE 
to transport magnesium and inhibit cytotoxicity toward CFBE  
• Specific Aim 3:  Test the effect of mutations in the magnesium binding sites on 
the ability of MgtE to transport magnesium and inhibit cytotoxicity toward CFBE. 
In addition to these three aims, we also evaluated the kinetics of cytotoxicity and the 
effects of extracellular magnesium concentration.  Overall, our results confirm the role of 
MgtE in regulation of cytotoxicity and begin to elucidate the importance of certain 
regions either for magnesium transport, cytotoxicity, or both.  By better understanding 
MgtE and P. aeruginosa, we are working toward our overarching goal of finding avenues 
toward improved health and quality of life for people with CF. 
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CHAPTER 2:  MATERIALS AND METHODS 
 
 
 
2.1  Bacterial Strains and Cell Cultures 
Four bacterial strains were used for this research (Table 1).  Bacterial cultures were 
grown overnight in LB at 37°C with shaking, and antibiotics were used at the following 
concentrations to maintain selectivity for the desired transformants:  50µg/mL gentamicin 
for P. aeruginosa; 10µg/mL gentamicin for E. coli and Salmonella.  The addition of 
100mM MgSO4 was necessary for maintenance growth of Salmonella MM281 without 
plasmids. 
 
2.2  Plasmids 
Plasmids used in this study are listed in Table 2 and illustrated in Figure 2.  New 
recombinant plasmids were created by utilizing homologous recombination in yeast, 
described below.  Full-length and mutant mgtE constructs were ligated into expression 
vector pMQ72 [41], which includes a gentamicin resistance gene to allow for selectivity 
of the desired transformants. 
 
2.3  Yeast Transformation 
Plasmid pBC101 is a replacement of the transmembrane domain of MgtE with the 
heterologous transmembrane protein DgkA, a diacylglycerol kinase found in P. 
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aeruginosa.  The recombinant plasmid was created as follows:  dgkA was PCR amplified 
from strain PA14 using primers DgkAfusfwd and DgkAfusrev (Table 3) and verified by 
gel electrophoresis on 1% agarose gel (Figure 3).  Plasmid pGA200 was digested with 
HindIII.  The dgkA fragment and digested plasmid were then joined by homologous 
recombination in yeast Saccharomyces cerevisiae using the following method known as 
“Lazy Bones” Protocol [42].  Yeast cultures were grown overnight in 5mL YEPD.  The 
culture was transferred to 1.5mL tubes and centrifuged to pellet cells.  Supernatant was 
drawn off, and the pellet was washed with 500µL TE.  TE was drawn off, and 500µL of 
Lazy Bones Solution (40% polyethylene glycol, 0.1M lithium acetate, 10mM Tris-HCl 
pH 7.5, 1mM EDTA) [42] was added.  Carrier DNA (sheared salmon sperm DNA) was 
heated for 10 minutes at 100°C, and then 20µL was added to the transformation reaction.  
10µL of digested plasmid pGA200 and 20µL of amplified dgkA fragment were added.  
The mixture was vortexed for one minute and then incubated at room temperature 
overnight for two nights.  The tube was heated at 42°C for 12 minutes to heat shock cells, 
and then centrifuged to pellet.  Supernatant was drawn off, and the pellet was 
resuspended in 1mL TE.  The sample was centrifuged again, and all but 100µL of the 
supernatant was drawn off.  Remaining sample was plated on uracil dropout media and 
incubated at 30°C for 4 days.  A control reaction was also prepared, which included all 
reagents as described above, except no DNA was added from salmon sperm, pGA200 
plasmid digest, or dgkA fragment.  Transformants were selected by growth on uracil 
dropout media.  Control plate had no growth. 
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Plasmids pBC102, pBC103, and pBC104 are a series of truncations of the MgtE N-
terminus.  These were constructed in the same manner just described, except that mgtE 
fragments were ligated into expression vector pMQ72. 
 
2.4  Plasmid Purification from Yeast 
Recombinant plasmids were purified from S. cerevisiae as follows.  Transformed 
yeast colonies were scraped from the agar plate and resuspended in 1mL YEPD.  The 
culture was centrifuged for one minute, and supernatant was drawn off.  The pellet was 
resuspended in 500µL sterile ddH2O, centrifuged, and supernatant was drawn off.  The 
pellet was resuspended in 250µL QIAGEN Buffer P1 from QIAprep Spin Miniprep Kit 
(Catalog #27106, QIAGEN Inc., Valencia, CA).  Two hundred fifty microliters of 
QIAGEN Buffer P2 and 250µL of glass beads were added.  The sample was vortexed for 
2 minutes and allowed to incubate on ice for 5 minutes.  Next, 350µL of chilled QIAGEN 
Buffer N3 were added, mixed by inverting, then incubated on ice for 5 minutes.  The 
sample was centrifuged for 10 minutes at maximum speed in a tabletop centrifuge.  
Supernatant was applied to the QIAprep spin column, and remaining steps were followed 
according to the kit protocol to elute the plasmid DNA. 
 
2.5  Bacterial Transformation 
Plasmids purified from yeast were transformed into E. coli S17 [43] by a rapid 
electroporation method, described by Choi et al [44].  Transformed cultures were plated 
on selective media and grown overnight at 37°C.  Individual colonies were then streaked 
for isolation on the same selective media and again grown overnight.  From this plate, an 
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individual colony was selected and grown in 5mL liquid LB with selective antibiotic.  
Following overnight growth, transformations were verified by PCR and gel 
electrophoresis.  In some cases, transformations were also verified by sequencing.  Once 
verified, plasmids were purified from E. coli using a QIAprep Spin Miniprep Kit.  
Purified plasmids were transformed by electroporation into PA14, GGA52 (∆mgtE), and 
MM281. 
 
2.6  Tissue Culture 
Tissue cultures of human-derived cystic fibrosis bronchial epithelial (CFBE) cells 
[45] were maintained in 750mL polystyrene culture flasks at 37°C in 5% CO2, and media 
was changed every 2 to 3 days.  Media was prepared by filter sterilization of minimal 
essential medium (MEM 1X, Cellgro® Minimal Essential Medium Eagle, Mediatech Inc., 
Manassas, VA) plus 10% fetal bovine serum, 50U/mL penicillin, and 50µg/mL 
streptomycin.  After cells were grown to confluence (Figure 4), typically in 7 to 10 days, 
the culture was divided into new flasks and clear polystyrene multi-well tissue culture 
plates as needed for assays.  To divide the confluent monolayer, the existing media was 
aspirated, and cells were washed with 20mL PBS.  Eight milliliters of trypsin (Cellgro® 
Trypsin EDTA 1X, Mediatech Inc., Manassas, VA) were added to the flask, and cells 
were incubated for 15 minutes at 37°C.  This allowed detachment of the CFBE cells from 
the flask.  Cells were removed by pipette, placed in a 15mL conical tube with 4mL 
standard tissue culture media to deactivate trypsin, and centrifuged for 5 minutes at 4400 
RPM to obtain a pellet.  All but 2mL of supernatant was drawn off, and the pellet was 
resuspended in the remaining supernatant.  Cell concentration was determined by count 
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on hemacytometer, and the volume of cells needed to seed new flasks and plates was 
calculated.  New flasks were typically seeded at a concentration of 2 x 106 cells/mL, and 
24-well plates were seeded at a concentration of 2 x 105 cells/mL.  Work with tissue 
cultures was performed in a sterile hood using aseptic technique. 
 
2.7  Co-culture Model System and Cytotoxicity Assay 
A great deal of our understanding of biofilms has been gained through studies of 
formation on abiotic surfaces.  Living tissue, and in particular the CF lung, provides a 
dramatically different environment for bacterial growth.  The co-culture model system 
was developed by Anderson et al. in order to provide a means to study P. aeruginosa 
virulence toward CF airway epithelial cells [46].  Promega CytoTox 96® Non-
Radioactive Cytotoxicity Assay kit (Part# G1780, Promega, Madison, WI) was used for 
all assays.  This colorimetric assay measures levels of lactate dehydrogenase (LDH), a 
cytosolic protein which is released into the culture supernatant when cells are lysed.  The 
color results from two coupled enzymatic reactions.  First, in the presence of LDH, 
NAD+ and lactate are converted to pyruvate and NADH.  Next, in the presence of 
diaphorase and tetrazolium salt (Promega Substrate Mix, proprietary composition), 
NADH is oxidized to NAD+, and formazan forms, which is red or dark pink in color.  
Darker shades are indicative of more LDH release and therefore higher cytotoxicity 
(Figure 5).  Cytotoxicity can then be analyzed quantitatively using a spectrophotometer to 
gather absorbance data. 
In preparation, CFBE cells were grown in multi-well tissue culture plates for 7 to 10 
days to reach confluence, and bacterial cultures were grown overnight.  To verify even 
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growth of bacterial cultures, serial dilutions were plated to obtain approximate count of 
colony forming units.  CFBE cells were washed with 500µL PBS (Cellgro® Dulbecco’s 
Phosphate-Buffered Saline without calcium and magnesium, Mediatech Inc., Manassas, 
VA) and then given 500µL fresh media containing MEM without phenol red (Cellgro® 
Minimal Essential Medium Eagle, Mediatech Inc., Manassas, VA), plus 2mM glutamine.  
Next, 3µL of bacteria were added to each well, and the assay plate (Figure 5) was placed 
in a 37°C incubator.  After one hour, media was replaced with the same media with 
addition of 0.4% arginine.  At timepoints, 300µL samples of supernatant were taken, 
placed in microcentrifuge tubes, and centrifuged for 2 minutes at 13,200 RPM.  Fifty 
microliters of this supernatant were then transferred to a clear, 96-well flat bottom plate, 
and 50µL of Substrate Mix were added to each sample.  Plates were incubated in the dark 
at room temperature for 30 minutes to allow assay color to develop.  Fifty microliters of 
Stop Buffer were added, and any bubbles that had formed were popped with a needle.  
Plate was placed in a SpectraMax M2 spectrophotometer and absorbance read at 490nm.  
Data was normalized to maximum release of LDH by CFBE cells treated with Triton® X-
100 Lysis Solution (supplied in assay kit). 
 
2.8  Magnesium Transport Assay 
The ability of mgtE mutants to transport magnesium was measured using Salmonella 
enterica Typhimurium MM281, a strain created for the purpose of testing magnesium 
transport constructs for their ability to restore growth without magnesium 
supplementation [47].  MM281 contains mutations in all of its magnesium transporters 
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and is unable to grow unless supplemented with 100mM magnesium or transformed with 
a functional magnesium transporter. 
In this study, MM281 was transformed with mgtE plasmids.  Mutants were grown 
overnight in 3mL LB supplemented with 100mM magnesium and 10µg/mL gentamicin 
to maintain selectivity for transformed bacteria.  Following overnight growth, 5µL of the 
culture was plated on N-minimal media [48] containing 10µg/mL gentamicin, and plates 
were incubated at 37°C for 1 to 2 days.   
Growth indicated complementation of magnesium transport (Figure 6).  All plates 
included MM281pGA200 (full-length mgtE) as a positive control, and MM281pMQ72 
(empty vector) as a negative control.  If an mgtE mutant construct did not grow in this 
assay, we concluded that the mutated region was essential for magnesium transport 
(Table 4).  Inversely, if growth occurs, then the mutated region of mgtE was not essential 
for magnesium transport. 
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CHAPTER 3:  RESULTS 
 
 
 
3.1  Regions of MgtE Essential to Magnesium Transport 
Magnesium transport was assessed using Salmonella enterica Typhimurium MM281, 
which is unable to transport magnesium (see Materials and Methods, Section 2.8).  We 
transformed MM281 with plasmids carrying various mutations of mgtE (Table 2, Figure 
2), and samples of the transformed cultures were plated on minimal media without 
magnesium.  Cultures would grow only if the mgtE plasmid restored ability to transport 
magnesium (Figure 6).  For the purpose of structure-function analysis, we concluded that 
if a particular mgtE mutation failed to grow, then the mutated region was essential for 
magnesium transport.  Inversely, if an mgtE mutant was able to restore growth in 
MM281, then the mutated region was non-essential to magnesium transport function.  
Results of magnesium transport assays are summarized in Table 4. 
It was predicted that C-terminal truncations would not transport magnesium because 
mutations in this region would be unlikely to form a functional transmembrane pore.  A 
total of six C-terminal mutations of MgtE were tested:  The five transmembrane alpha-
helices were truncated one at a time, and the entire transmembrane domain was also 
replaced with the heterologous transmembrane protein DgkA (Figure 2).  As anticipated, 
these mutations failed to complement magnesium transport in Salmonella MM281, with 
one interesting exception, pGA203. 
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There was anomalous, spotty growth for the construct pGA203, which is a truncation 
of transmembrane domains 3, 4, and 5 (see Figure 6A).  Results were replicated four 
times.  It was suspected that the spotty growth of MM281pGA203 may have been the 
result of a contaminated or mixed culture, or perhaps a spontaneous mutation in the lab 
stock culture.  To examine this, we sub-cultured and re-plated several generations.  We 
found that the spotty growth persisted through sub-cultures of the original stock.  
However, when individual spot colonies were selected from a plate, and either streaked 
for isolation or grown overnight in liquid media and then plated, solid growth occurred.  
Of the six C-terminal mutations of mgtE, pGA203 was the only construct shown to 
transport magnesium, and also demonstrated the lowest level of cytotoxicity compared to 
the other C-terminal mutations. 
To further investigate the possibility of a mutation in the MM281pGA203 culture, 
DNA sequencing was performed on a stock sample and two samples from magnesium 
transport assays.  Data obtained from the Indiana University School of Medicine DNA 
Sequencing Core Facility indicated no spontaneous mutation in mgtE.  Although there 
was some growth shown by pGA203, it is unlikely that this construct is able to form a 
functional transmembrane pore;  therefore, I have concluded that the full transmembrane 
domain is essential for magnesium transport. 
It was anticipated that individual magnesium binding site mutations would not cause 
complete disruption of magnesium transport.  There are a total of seven proposed 
magnesium binding sites in the MgtE monomer, one in the transmembrane domain and 
six in the cytosolic domain [34], and since they work cooperatively, it seems that 
mutation in one of the cytosolic sites would not necessarily result in complete 
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dysfunction of the protein.  Binding site 1 is located in the transmembrane pore, while 
sites 2 through 6 are in the cytosolic region.  Results demonstrated that magnesium 
binding sites 2 through 6 (cytosolic region) were not individually essential for 
magnesium transport, although binding site 1 (pore region) was essential.  Our tests did 
not include mutations in the seventh putative magnesium binding site, which is also in the 
cytosol.  Given that other studies have shown the MgtE pore to be highly specific for 
magnesium ions [34], it is not surprising that a mutation in this region would impair 
magnesium transport function.  Magnesium binding site 1 has also been shown to be less 
conserved between bacterial species than the other binding sites [49].  Mutations of 
binding sites 2 and 3, which are located in the connecting helix, were combined in one 
plasmid (pGA207), and still this construct was able to transport magnesium.  The 
connecting helix region is of particular interest because mutation of this region 
demonstrated separation of function between magnesium transport and regulation of 
cytotoxicity, which will be discussed further in the next section. 
Results of magnesium transport assays suggest that the entire N-terminal intracellular 
domain is essential for full complementation of magnesium transport (Figure 6).  This is 
consistent with the findings of Hattori et al. which state that the cytosolic domain of 
MgtE functions to sense intracellular magnesium levels and regulate the opening and 
closing of the transmembrane pore [34].  Although it was anticipated that N-terminal 
truncations would impair or eliminate magnesium transport function, we obtained an 
interesting result, which was replicated in triplicate.  The shortest N-terminal truncation 
(pBC102) resulted in weak growth compared to full-length mgtE (Figure 6D).  No growth 
was seen with a longer truncation which included the globular N-domain.  And spotty 
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growth, similar to that seen for C-terminal truncation pGA203, appeared from the longest 
truncation.  Possible variation in results due to plating technique was addressed by plating 
duplicate samples of each culture.  Samples were also checked by PCR to assure that they 
were not cross-contaminated. 
 
3.2  Regions of MgtE Essential to Regulation of Cytotoxicity 
Our goal was to determine which regions of MgtE were critical to regulating P. 
aeruginosa cytotoxicity.  Specifically, we wanted to measure cytotoxicity toward CFBE 
cells.  Cytotoxicity was assessed using a colorimetric assay to measure LDH release from 
CFBE cells incubated with bacteria. 
To determine which regions of MgtE are essential for the regulation of cytotoxicity, 
the P. aeruginosa strain GGA52 (PA14 ∆mgtE), was transformed with plasmids carrying 
various mutations of mgtE (see Table 2).  Levels of cytotoxicity were compared to wild 
type P. aeruginosa PA14 with empty vector pMQ72, GGA52 with overexpression of 
full-length mgtE (pGA200), and GGA52 with empty vector pMQ72.  Results of 
cytotoxicity assays are represented in Figures 7, 8, 9. 
Results support previous research demonstrating that overexpression of MgtE inhibits 
cytotoxicity of P. aeruginosa toward CFBE cells [31].  Anderson et al. demonstrated that 
this occurs through inhibition of transcription of the type III secretion system. 
As expected, C-terminal truncations had a significant effect on the regulation of 
cytotoxicity (Figure 7), as did the replacement of the transmembrane domain (Figure 8).  
C-terminal mgtE mutants were assayed over 20 times, and although there was 
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considerable variation in the raw data, there was a consistent trend showing mutants’ loss 
of cytotoxicity regulation compared to overexpression of mgtE. 
Magnesium binding site point mutations had widely different effects on cytotoxicity, 
depending on their location in the protein (Figure 9).  A mutation in the transmembrane 
pore (pGA206) resulted in loss of inhibitory function, but the greatest loss of function 
was observed in mutation pGA207, which is in the connecting helix region.  This was the 
only mutant which retained magnesium transport function while losing regulation of 
cytotoxicity. 
In seven independent experiments of N-terminal mgtE mutants, it was observed that 
progressive truncations resulted in progressive loss of regulation of cytotoxicity (Figure 
8).  The shortest truncation (pBC102), which is a deletion of 37 amino acids, 
demonstrates regulation of cytotoxicity comparable to overexpression of mgtE (pGA200).  
The magnesium transport function was diminished in this mutant, making pBC102 our 
second construct that displays a separation of functions:  it regulates cytotoxicity, but has 
impaired magnesium transport function. 
 
3.3  Separation of Functions 
Two mgtE mutants were identified which demonstrated a separation between the 
functions of magnesium transport and regulation of cytotoxicity.  The mutations were 
expressed in plasmids pGA207 and pBC102.  Plasmid pGA207 carries point mutations in 
magnesium binding sites 2 and 3, located in the connecting helix.  Plasmid pBC102 is an 
N-terminal truncation of 37 amino acids. 
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Plasmid pGA207 was able to complement magnesium transport function, 
demonstrated by restored growth of Salmonella MM281;  however, in cytotoxicity 
assays, pGA207 was unable to regulate cytotoxicity, demonstrating levels of cytotoxicity 
similar to the mgtE deletion mutant GGA52.  In other words, mutation of the connecting 
helix region of MgtE does not impair magnesium transport function but does eliminate 
cytotoxicity regulating function.  Previous research on the structure of MgtE has 
suggested that in the magnesium-bound state, the magnesium binding sites in the 
connecting helix may maintain stability of the closed conformation, and that dimerization 
is facilitated by the N-terminal globular domains [34].  Thus, our structure-function 
analysis supports these findings by suggesting that dimerization can occur, but when 
magnesium is unable to bind in the connecting helix region, MgtE remains in an open 
conformation and allows the passage of ions. 
In plasmid pBC102, the N-terminal truncation of 37 amino acids resulted in 
diminished magnesium transport function (Figure 6D), while regulating cytotoxicity at 
levels comparable to over-expression of full-length mgtE (Figure 8).  This result is the 
inverse of that seen for pGA207, described above.  This means that we have shown 
magnesium transport without cytotoxicity regulation, and we have also shown 
cytotoxicity regulation without magnesium transport.  Combined, the results from these 
two mgtE mutants support the hypothesis that the functions of MgtE are separable. 
 
3.4  Effects of Magnesium Concentration 
Low serum magnesium levels are common in CF patients [50].  The concentration of 
magnesium in the CF lung has been shown to be 1.0-2.0mM [51], with serum magnesium 
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levels in the range of 0.46-1.03mM (normal range 0.74-1.1mM) [50].  We were interested 
to see if the concentration of magnesium in the growth media would affect the level of 
cytotoxicity of P. aeruginosa toward CFBE cells.  In other words, do extracellular 
magnesium levels impact the interaction between bacteria and host?  In the standard 
media for cytotoxicity assays, we varied the magnesium concentrations ranging from 
1µM to 10mM.  The standard magnesium concentration in our media is 0.8mM.  In the 
1µM to 1mM range, the cytotoxicity of wild type P. aeruginosa strain PA14 toward 
CFBE cells increased along with increases in magnesium concentration.  However, in the 
2mM to 10mM magnesium range, cytotoxicity levels remained fairly consistent and did 
not exceed the 1mM levels (Figure 10).  
This data suggests that extracellular magnesium levels affect host-pathogen 
interaction, although it does not tell us if magnesium levels affect cellular functions of the 
host, the pathogen, or both.  It would be interesting to test mgtE mutants’ response to 
varying concentrations of extracellular magnesium.  This might give us a clue as to which 
regions of the protein are most sensitive to extracellular magnesium levels. 
 
3.5  Kinetics of Cytotoxicity 
The cytotoxicity assays were 6-hour experiments.  We wanted to see if levels of 
cytotoxicity increased gradually over time, or if cytotoxicity reached a peak and then 
leveled off.  Also, we wanted to compare the kinetics of cytotoxicity in wild type PA14 to 
our mgtE mutants.  Representative results are shown in Figure 11.  Cytotoxicity increased 
over time up to 6 hours, with no plateau in any of the samples tested.  In mgtE mutants, 
levels of cytotoxicity increased markedly throughout the timecourse, while in wild type 
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PA14 and over-expressed full-length mgtE, cytotoxicity levels remained comparatively 
low until 4 hours, after which point they increased significantly.  Overall, these results 
suggest that cytotoxicity, if unregulated by MgtE, increases steadily over time; whereas, 
when the cytotoxicity-regulating function is intact, cytotoxicity may be inhibited to a 
greater degree in the earliest stages of host-pathogen interaction.  This could be due to 
different rates of bacterial growth or to expression levels of virulence factors. 
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CHAPTER 4:  DISCUSSION 
 
 
 
This research has demonstrated that MgtE functions as both a magnesium transporter 
and a regulator of cytotoxicity.  The goal to perform a structure-function analysis of 
MgtE was achieved, resulting in a better understanding of which regions of the protein 
are critical for magnesium transport and regulation of cytotoxicity.  The three specific 
aims of this project – to assess magnesium transport and regulation of cytotoxicity in 
three groups of mgtE mutants – were addressed experimentally through cytotoxicity 
assays and magnesium transport assays.  Additionally, work was completed to assess the 
kinetics of cytotoxicity and the effect of extracellular magnesium concentration. 
Previous studies have shown that the plasmid pGA200 (full-length MgtE) localizes to 
the inner membrane [31].  To support the results found in this study, I would like to 
assess membrane localization and protein expression levels of the mgtE mutants.  This 
would require a cell lysis method that is effective for Gram-negative bacteria and allows 
preservation of protein association with the inner membrane.  It will be particularly 
important to localize and quantitate the mgtE mutants that currently support my 
hypothesis of separation of functions. 
The hypothesis that the two functions of MgtE could be separated was supported by 
two mutant constructs.  Mutant pGA207, containing a point mutation in the connecting 
helix region, was able to transport magnesium, but did not regulate cytotoxicity.  Mutant 
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pBC102, a truncation of 37 amino acids from the N-terminus, inhibited cytotoxicity at 
levels similar to full-length mgtE, but showed only weak magnesium transport. 
The spotty growth of two mgtE mutants in magnesium transport assays was not 
considered as full growth comparable to wild type mgtE, and therefore these mutants 
were not considered to be transporting magnesium.  Our tests did not reveal an 
explanation for the spotty growth, but one possibility is that some cells in the culture 
developed suppressor mutations.  Suppressor mutations are spontaneous mutations, either 
in the gene of interest or elsewhere in the genome, which in essence override the effect of 
the intended mutation.  Suppressor mutations revert the phenotype to wild type [52].  
The complete transmembrane (C-terminal) domain was shown to be essential for full 
complement of magnesium transport as well as regulation of cytotoxicity.  This may be 
due to the necessity of all five TMDs for pore formation, insertion in the membrane, 
dimerization, or all of these.  Only one magnesium binding site was essential to 
magnesium transport; this site was located in the pore.  Since the remaining magnesium 
binding sites are cytosolic and thought to work cooperatively, it was not surprising to see 
magnesium transport function unaffected by their individual mutation. 
The cytosolic N-domain, however, tells a more complicated story.  None of the N-
terminal truncations were able to transport magnesium at a level comparable to full-
length mgtE, but the shortest truncation showed weak magnesium transport, and the 
longest truncation showed spotty growth.  With the first N-terminal truncation, inhibition 
of cytotoxicity was comparable to overexpression of full-length mgtE, but cytotoxicity-
regulating function was diminished with progressive truncations of the N-domain.  It has 
been previously shown that MgtE inhibits transcription of T3SS [31], but the mechanism 
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remains to be elucidated.  I propose that the cytosolic domain of MgtE contains an 
inhibitory region which may interact with the T3SS pathway to regulate release of 
cytotoxic effector molecules.  The need for further investigation of this interaction is 
reflected in the statement of Hattori et al., “…the function of the N domain remains 
elusive.” [34] 
Much of our structure-function analysis in P. aeruginosa is consistent with the 
findings of Hattori et al. in their work on the crystal structure of MgtE in Thermus 
thermophilus.  This is exciting because it suggests we are on track toward a better 
understanding of the role of MgtE in magnesium homeostasis. 
While there appears to be a correlation between magnesium transport and 
cytotoxicity, this research suggests that they are not necessarily inextricably linked.  A 
key finding of this study is that disruption of one function of MgtE does not always 
eliminate the other. 
In interpreting the results of these experiments, there are a couple of variables to 
consider.  First, the passage number of the CFBE cells can affect results.  In cytotoxicity 
assays, we observed that cells from higher passage numbers showed increased levels of 
LDH release.  In part, this is addressed by calculating cytotoxicity as a percentage of 
maximum LDH release rather than using raw spectrophotometer data.  Nevertheless, it is 
important to be mindful of the CFBE cell passage number when comparing data from 
independent experiments.  Second, it is difficult to assure uniformity of CFBE cell 
growth in every well of a 24-well plate, and in some cases up to three plates were used in 
each experiment.  Due to potential human error in seeding the plates, it is possible that a 
well could contain no CFBE cells, or twice the amount.  This problem can be addressed 
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at least in part by assaying samples in triplicate, but this limits the range of samples that 
can be assayed in a single experiment.  In an attempt to test a wide range of plasmid 
constructs at one time, some assays were run using 96-well plates, but it proved to be 
problematic to use a sample size unintended for this protocol.  Although efforts were 
made to adjust concentrations of bacteria and assay reagents to accommodate the smaller 
sample size, results were inconsistent with previous experiments. 
At present, there remains a lack of understanding of magnesium homeostasis and 
magnesium transport proteins, although the role of magnesium levels in pathogenesis has 
been recognized since studies of toxic shock syndrome in the 1980s [53, 54].  The future 
direction of this research could involve further investigation in several areas:  magnesium 
homeostasis in bacteria and both healthy and immunocompromised hosts;  structure and 
function of currently identified magnesium transport proteins, and perhaps others to be 
discovered;  bacterial regulation of cytotoxicity in various environments; and 
immunogenicity and pathogenesis pathways. 
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Table 1:  Experimental Organisms. 
 
 
Organism Description or Purpose Source
Bacterium Escherichia coli S17-1 laboratory cloning strain Simon et al.  1983
Bacterium Pseudomonas aeruginosa  PA14 wild type, clinical isolate Rahme et al.  1995
Bacterium Pseudomonas aeruginosa  GGA52 PA14 ∆mgtE Anderson et al.  2010
Bacterium Salmonella enterica  Typhimurium MM281 corA45 ::MudJ  mgtA21 ::MudJ  mgtB10 ::MudJ  
testing magnesium transport complementation
Hmiel et al.  1989
Human-derived cystic fibrosis bronchial epithelial cells CFTR ∆F508 Cozens et al.  1994
Yeast S. cerevisiae InvSc1 ura3-52 / ura3-52  ; creation of plasmids by 
homologous recombination
Invitrogen
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Table 2:  Description of Plasmids. 
 
 
Plasmid Description Source
pBC101 TMD replacement This project.
pBC102 N-terminal deletion (-111 base pairs) This project.
pBC103 N-terminal deletion (-303 base pairs) This project.
pBC104 N-terminal deletion (-324 base pairs) This project.
pBS23 Mg2+ binding site point mutation Anderson et al.
pGA200 full-length MgtE Anderson et al.
pGA201 C-terminal deletion, alpha helices 1-5 Anderson et al.
pGA202 C-terminal deletion, alpha helices 2-5 Anderson et al.
pGA203 C-terminal deletion, alpha helices 3-5 Anderson et al.
pGA204 C-terminal deletion, alpha helices 4-5 Anderson et al.
pGA205 C-terminal deletion, alpha helix 5 Anderson et al.
pGA206 Mg2+ binding site 1 (pore), point mutation Anderson et al.
pGA207 Mg
2+ binding sites 2/3 (connecting helix), point 
mutation
Anderson et al.
pGA208 Mg2+ binding site 4 (cytosol), point mutation Anderson et al.
pGA209 Mg2+ binding site 5 (cytosol), point mutation Anderson et al.
pGA210 Mg2+ binding site 6 (cytosol), point mutation Anderson et al.
pMQ72 control empty expression vector with gentamicin-
resistance gene
Shanks et al.
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Table 3:  Primers. 
 
 
Primer Description Sequence (5' - 3')
729
verify mgtE 
mutants CAGACCGCTTCTGCGTTCTG
730
verify mgtE 
mutants GCAACTCTCTACTGTTTCTCC
913Nleftfor 
construct mgtE 
mutants TCGAGATAACCGTTGGCCTC 
913Nrightrev 
construct mgtE 
mutants CAGACCGCTTCTGCGTTCTG
913Nrightfor
construct mgtE 
mutants
GAATTCAGGAGGAGCGCGCTATGGAAGGCCAGCA
CCATGACCG 
913Nleftrev 
construct mgtE 
mutants
CGGTCATGGTGCTGGCCTTCCATAGCGCGCTCCTCC
TGAATTC 
DgkAfusfwd
construct mgtE 
mutants
GCAAGTGCTGGAAGTCATGGCCACCGACCCGGTGA
CCTTCGTGTCGCCTTCCCCCTTCAA
DgkAfusrev
construct mgtE 
mutants
CTGTATCAGGCTGAAAATCTTCTCTCATCCGCCAA
AACAGTCAGCCCAGCAGGATGGTCG
MgtNCBSDelRfor
N-terminal 
truncations
GAATTCAGGAGGAGCGCGCTATGGAAGTCCTCAA
CATGGCCGGTC 
MgtNDomDelRfor
N-terminal 
truncations
GAATTCAGGAGGAGCGCGCTATGGAAAGCCTCGA
CGCGCAGCAG 
MgtNDomDelLrev 
N-terminal 
truncations
CTGCTGCGCGTCGAGGCTTTCCATAGCGCGCTCCTC
CTGAATTC 
MgtNCBSDelLrev
N-terminal 
truncations
GACCGGCCATGTTGAGGACTTCCATAGCGCGCTCC
TCCTGAATTC 
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Table 4:  Summary of Magnesium Transport Assays. 
 
 
Plasmid Brief Description Transports    
Magnesium
pBC101 TMD (C-terminal) replacement NO
pBC102 N-terminal deletion WEAKLY
pBC103 N-terminal deletion NO
pBC104 N-terminal deletion SPOTTY
pBS23 Mg2+ binding site point mutation NO
pGA200 full-length MgtE YES
pGA201 C-terminal deletion NO
pGA202 C-terminal deletion NO
pGA203 C-terminal deletion SPOTTY
pGA204 C-terminal deletion NO
pGA205 C-terminal deletion NO
pGA206 Mg2+ binding site point mutation NO
pGA207 Mg2+ binding site point mutation YES
pGA208 Mg2+ binding site point mutation YES
pGA209 Mg2+ binding site point mutation YES
pGA210 Mg2+ binding site point mutation YES
pMQ72 control empty vector NO
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Figure 1:  Structure of MgtE.  The crystal structure of MgtE was resolved in Thermus 
thermophilus in 2007 by Hattori et al.  (A):  MgtE is believed to function as a 
homodimer.  Figures depict one monomer in color, with the transmembrane domain in 
red, the connecting (plug) helix in yellow, the CBS domain in green, and the N domain in 
blue.  The other monomer is shown in gray.  (B):  Figure illustrates seven putative 
magnesium binding sites, with magnesium ions shown as purple balls. 
 
Hattori, M., et al., Mg(2+)-dependent gating of bacterial MgtE channel underlies 
Mg(2+) homeostasis. EMBO J, 2009. 28(22): p. 3602-12. 
 
 
(A) (B) 
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Figure 2:  Schematic of MgtE Mutations.  Mutations were made to the mgtE gene and 
cloned into the pMQ72 expression vector.  Plasmid pGA200 carries full-length mgtE 
with no mutations.  Plasmids pGA201 through pGA205 carry C-terminal truncations.  
Plasmids pGA206 through pGA210 carry point mutations in the magnesium binding 
sites.  pBC101 is a replacement of the entire transmembrane domain.  pBC102 through 
pBC104 are N-terminal truncations.  As shown, relative lengths and positions of protein 
domains are purely diagrammatic and not to scale.   
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Plasmid 37 aa
N-
domain
CBS 
domain 1 2 3 4 5 6
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Transmembrane Domains
C-terminus
1448 base pairs
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Figure 3:  PCR of DkgA.  DgkA is a heterologous transmembrane protein in P. 
aeruginosa which was used to replace the transmembrane domain in MgtE.  dgkA was 
PCR amplified from strain PA14 using primers DgkAfusfwd and DgkAfusrev.  Lane 1:  
Molecular weight marker.  Lane 2:  Plasmid pGA200.  Lane 3:  Plasmid pGA200 
digested with HindIII.  Lane 4:  PCR amplified fragment of dgkA.  Expected fragment 
size is 372 base pairs.  Gel electrophoresis was performed on 1% agarose gel. 
 
(1) (2) (3) (4) 
dgkA 
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  2 days’ CFBE cell growth 
 
  4 days’ CFBE cell growth 
 
  7-10 days, confluent monolayer of CFBE cells 
 
Figure 4:  Cystic Fibrosis Bronchial Epithelial Cells.  Immortalized human-derived 
cells express CFTR ∆F508, the mutation most often found to be the cause of cystic 
fibrosis. 
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Figure 5:  Cytotoxicity Assay.  Top image is a 24-well tissue culture plate in which 
CFBE cells have been growing for 7-10 days to reach confluent monolayer.  Bacterial 
cultures were added for assay.  Wells are labeled according to the plasmid constructs 
being tested.  Bottom image is 96-well microtiter plate containing assayed samples.  
Darker color indicates higher level of cytotoxicity, measured by LDH release. 
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Figure 6:  Magnesium Transport Assays.  Ability of mgtE mutants to complement 
magnesium transport was assessed by growth on minimal media.  Growth is observed as 
white, cloudy areas.  pMQ72 is empty vector used as negative control.  pGA200 is full-
length mgtE used as positive control.  (A), (B):  Magnesium transport complementation 
by mgtE with C-terminal truncations of transmembrane domains, plasmids pGA201 
through pGA205.  Anomalous spotty growth is visible in pGA203.  (B), (C):  
Magnesium transport complementation by mgtE with magnesium binding site mutations, 
plasmids pGA206 through pGA210.  (D):  Magnesium transport complementation by 
mgtE with N-terminal truncations, plasmids pBC101 through pBC104.  Light growth is 
seen in pBC102, and spotty growth is visible in pBC104. 
(A) (B) 
(C) 
 
(D) 
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Figure 7:  Cytotoxicity Assays, C-Terminal Truncations.  C-terminal truncations 
(lanes 4-8) demonstrate decreased regulation of cytotoxicity compared to overexpression 
of full-length MgtE (lane 3).  These results suggest that the full C-terminal 
transmembrane domain is required for regulation of cytotoxicity.  The X-axis displays 
controls and plasmid constructs.  On the Y-axis, percent cytotoxicity is normalized as a 
percentage of maximum LDH release by CFBE cells following treatment with Triton® X-
100.  Lane 1 is wild type PA14 with empty vector.  Lane 2 is GGA52 (PA14∆mgtE) with 
empty vector.  Lane 3 is GGA52 with pGA200 (full-length MgtE).  Lanes 4, 5, 6, 7, and 
8 are progressive truncations of the five C-terminal transmembrane alpha-helices.  Data is 
representative of 20 independent experiments.  *, P < 0.05. 
(1) (2) (3) (5) (4) (6) (7) (8) 
* 
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Figure 8:  Cytotoxicity Assays, N-Terminal Truncations and TMD Replacement.  
Results demonstrate that increasing truncations of the N-terminal region of MgtE result in 
increasing loss of regulation of cytotoxicity.  Replacement of the C-terminal 
transmembrane domain with a heterologous transmembrane protein also results in 
inability to regulate cytotoxicity.  The X-axis displays controls and plasmid constructs.  
On the Y-axis, percent cytotoxicity is normalized to maximum LDH release by CFBE 
cells following treatment with Triton® X-100.  Lane 1 is GGA52 (PA14 ∆mgtE) with 
empty vector.  Lane 2 is GGA52 with pGA200 (full-length MgtE).  Lane 3 (pBC101) is a 
replacement of the transmembrane domain with the heterologous transmembrane protein 
DgkA.  Lane 4 (pBC102) is a truncation of 37 amino acids (111 base pairs) from the N-
terminus.  Lane 5 (pBC103) is a deletion of 303 N-terminal base pairs.  Lane 6 (pBC104) 
is a truncation of 324 N-terminal base pairs.  Data is representative of 7 independent 
experiments.  *, P < 0.05. 
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Figure 9:  Cytotoxicity Assays, Magnesium Binding Site Point Mutations.  Results 
demonstrate varying effects of magnesium binding site mutations on the regulation of 
cytotoxicity.  Data also suggests that the magnesium binding site in the transmembrane 
pore (pGA206, lane 2) is essential for regulating cytotoxicity.  The X-axis displays 
controls and plasmid constructs.  On the Y-axis, percent cytotoxicity is normalized to 
maximum LDH release by CFBE cells following treatment with Triton® X-100.  All 
lanes are GGA52 (PA14 ∆mgtE) with plasmids.  Lane 1 is full-length MgtE.  Lane 2 is 
magnesium binding site 1, located in the transmembrane domain.  Lane 3 is binding sites 
2 and 3, located in the connecting helix.  Lanes 4, 5, and 6 are point mutations in the CBS 
(cytosolic) domain.  Data is representative of 20 independent experiments. 
*, P < 0.05. 
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Figure 10:  Magnesium Concentration.  Levels of extracellular magnesium affect wild 
type P. aeruginosa PA14 cytotoxicity toward CFBE cells.  As magnesium concentrations 
in the media were increased from 1µM to 1.0mM, a corresponding increase in 
cytotoxicity was observed.  No further increases in cytotoxicity were noted at 
concentrations of 2mM to 10mM. 
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Figure 11:  Kinetics of Cytotoxicity.  Levels of cytotoxicity increase over time.  In 
mgtE mutants, cytotoxicity increases more rapidly between 2 and 4 hours compared to 
wild type and over-expression of full-length mgtE.  Construct 52pGA200 is over-
expression of full-length mgtE.  52pGA207 is a mutation in magnesium binding sites 2 
and 3, shown in previous experiments to lack cytotoxicity-regulating function.  52pMQ72 
is empty expression vector.  Results are representative of three independent experiments. 
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